Cargando…

Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia

The treatment of hypercholesterolemia entered in a new phase of development with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the market. The Food and Drug Administration and European Medicines Agency recently approved the alirocumab and evolocumab, subcuta...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazhar, Faizan, Haider, Nafis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242035/
https://www.ncbi.nlm.nih.gov/pubmed/28163543
http://dx.doi.org/10.4103/0976-500X.195906
_version_ 1782496286919884800
author Mazhar, Faizan
Haider, Nafis
author_facet Mazhar, Faizan
Haider, Nafis
author_sort Mazhar, Faizan
collection PubMed
description The treatment of hypercholesterolemia entered in a new phase of development with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the market. The Food and Drug Administration and European Medicines Agency recently approved the alirocumab and evolocumab, subcutaneously injectable monoclonal antibody every 2 or 4 weeks against PCSK9, for the treatment of hypercholesterolemia in patients with intolerance or inadequate response to statins, especially for the secondary prevention or in the case of familial hypercholesterolemia. This decision is based on several clinical trials demonstrating that inhibitors of PCSK9 lower the low-density lipoprotein cholesterol compared to placebo while studies are underway to assess their role in secondary prevention of major cardiovascular events.
format Online
Article
Text
id pubmed-5242035
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-52420352017-02-03 Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia Mazhar, Faizan Haider, Nafis J Pharmacol Pharmacother Molecules of Millennium The treatment of hypercholesterolemia entered in a new phase of development with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the market. The Food and Drug Administration and European Medicines Agency recently approved the alirocumab and evolocumab, subcutaneously injectable monoclonal antibody every 2 or 4 weeks against PCSK9, for the treatment of hypercholesterolemia in patients with intolerance or inadequate response to statins, especially for the secondary prevention or in the case of familial hypercholesterolemia. This decision is based on several clinical trials demonstrating that inhibitors of PCSK9 lower the low-density lipoprotein cholesterol compared to placebo while studies are underway to assess their role in secondary prevention of major cardiovascular events. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5242035/ /pubmed/28163543 http://dx.doi.org/10.4103/0976-500X.195906 Text en Copyright: © 2016 Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Molecules of Millennium
Mazhar, Faizan
Haider, Nafis
Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
title Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
title_full Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
title_fullStr Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
title_full_unstemmed Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
title_short Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
title_sort proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: an emerging new therapeutic option for the treatment of dyslipidemia
topic Molecules of Millennium
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242035/
https://www.ncbi.nlm.nih.gov/pubmed/28163543
http://dx.doi.org/10.4103/0976-500X.195906
work_keys_str_mv AT mazharfaizan proproteinconvertasesubtilisinkexintype9enzymeinhibitorsanemergingnewtherapeuticoptionforthetreatmentofdyslipidemia
AT haidernafis proproteinconvertasesubtilisinkexintype9enzymeinhibitorsanemergingnewtherapeuticoptionforthetreatmentofdyslipidemia